Evidence map›Paper›PMID 38424421›Full record

ReviewCurrent protein & peptide science2024

A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy.

Felipe Pantoja Mesquita, Luina Benevides Lima, Emerson Lucena da Silva, Pedro Filho Noronha Souza, Maria Elisabete Amaral de Moraes, Rommel Mario Rodrigues Burbano, Raquel Carvalho Montenegro

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current protein & peptide science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Felipe Pantoja MesquitaLaboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, 60430-275, Brazil.
Luina Benevides LimaLaboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, 60430-275, Brazil.
Emerson Lucena da SilvaLaboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, 60430-275, Brazil.
Pedro Filho Noronha SouzaLaboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, 60430-275, Brazil.ORCID 0000-0003-2524-4434
Maria Elisabete Amaral de MoraesLaboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, 60430-275, Brazil.
Rommel Mario Rodrigues BurbanoDepartment of Biological Sciences, Oncology Research Center, Federal University of Pará, Belém, Brazil.
Raquel Carvalho MontenegroLaboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE, 60430-275, Brazil.
Universidade Federal do Ceará · BRUniversidade Federal do Pará · BR

Funding

National Council for Scientific and Technological Development (CNPq) 403493/2021-8, 305459/2019-8, 305003/2022-4, 421392/2023-1
6 · The paper itself

Abstract

Gastric adenocarcinoma is a complex disease with diverse genetic modifications, including Anaplastic Lymphoma Kinase (ALK) gene changes. The ALK gene is located on chromosome 2p23 and encodes a receptor tyrosine kinase that plays a crucial role in embryonic development and cellular differentiation. ALK alterations can result from gene fusion, mutation, amplification, or overexpression in gastric adenocarcinoma. Fusion occurs when the ALK gene fuses with another gene, resulting in a chimeric protein with constitutive kinase activity and promoting oncogenesis. ALK mutations are less common but can also result in the activation of ALK signaling pathways. Targeted therapies for ALK variations in gastric adenocarcinoma have been developed, including ALK inhibitors that have shown promising results in pre-clinical studies. Future studies are needed to elucidate the ALK role in gastric cancer and to identify predictive biomarkers to improve patient selection for targeted therapy. Overall, ALK alterations are a relevant biomarker for gastric adenocarcinoma treatment and targeted therapies for ALK may improve patients' overall survival.

Indexed as

Anaplastic Lymphoma KinaseMolecular Targeted TherapyMutationProtein Kinase InhibitorsStomach NeoplasmsAdenocarcinomaBiomarkers, TumorGene RearrangementHumansSignal TransductionALK protein, humanAnaplastic Lymphoma KinaseBiomarkers, TumorProtein Kinase InhibitorsALKbiomarkergastric cancerGastric carcinogenesisgene fusion.targeted therapy

Identifiers

PMID38424421
OpenAlexW4392352165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.